{"id":1073,"date":"2023-02-27T14:05:00","date_gmt":"2023-02-27T14:05:00","guid":{"rendered":"https:\/\/new.www.purdue.edu\/newsroom\/?p=1073"},"modified":"2024-08-20T14:27:24","modified_gmt":"2024-08-20T18:27:24","slug":"novilytic-preps-for-expansion-with-launch-of-new-proteometer-l","status":"publish","type":"post","link":"https:\/\/www.purdue.edu\/newsroom\/2023\/Q1\/novilytic-preps-for-expansion-with-launch-of-new-proteometer-l","title":{"rendered":"Novilytic preps for expansion with launch of new Proteometer-L"},"content":{"rendered":"

WEST LAFAYETTE, Ind. —<\/p> \n

Novilytic LLC<\/a>, a molecular-recognition company that uses nanotechnology to monitor the quality of lifesaving medicines, has released its first product, the Proteometer-L. The company\u2019s goal is that sales from the product will enable rapid hiring for its commercialization and science teams and expansion into a second location in Indianapolis.<\/p>\n<\/div>\n\n\n

Short for \u201cproteoform meter,\u201d the\u00a0Proteometer-L<\/a>\u00a0is sold in a kit as the world\u2019s first technology for at-line molecular structure analysis and quantification. It is compatible with bioreactors and performs analyses of medicinal batches roughly every 10 minutes. The new tech enables process R&D scientists and drug manufacturers to recognize when a product run is going awry in near real time.<\/p>\n\n\n

\n
\"\"
The Proteometer-L from Novilytic is sold in a kit that includes the device, buffers, reagents and instructions. The product launch comes on the heels of successful pilot programs with large instrument manufacturers and contract development and manufacturing organizations. (Photo provided by Novilytic)<\/figcaption><\/figure>\n<\/div>\n\n\n

\u201cThis quick analysis saves up to six-plus hours a day and over $1 million per batch, increasing both profits and FDA compliance,\u201d said Fred Regnier, PhD, Novilytic CTO and emeritus professor of chemistry at Purdue University. \u201cThe Proteometer kit is designed as a \u2018plug and play\u2019 consumable, ensuring easy adoption in almost all of the more than 250,000 instruments currently used in the pharmaceutical industry.\u201d<\/p>\n\n\n\n

Novilytic\u2019s first product launch comes on the heels of successful pilot programs with large instrument manufacturers and contract development and manufacturing organizations, or CDMOs. These successful pilots have led to discussions for sales contracts that the company hopes to announce soon.<\/p>\n\n\n\n

\u201cWith this as our official foray into commercialization, we are being incredibly diligent to cross our t\u2019s and dot our i\u2019s. The goal of our numerous pilot programs was to demonstrate that our solution works in potential customers\u2019 laboratories, not just ours,\u201d said Paul Dreier, Novilytic CEO. \u201cWe are thrilled to share that our customer training was less than one hour, and the pilot data looks as good and even better than ours in many cases.\u201d<\/p>\n\n\n\n

The development of the Proteometer-L was made possible due to a $1.6 million funding round with multiple investors, including the\u00a0Purdue Research Foundation<\/a>. These funds provided the basis for Novilytic to test multiple drugs currently on the market, proving that the\u00a0patented Luminon\u00ae and MASC\u00ae technology<\/a>\u00a0in fact works in a real-world setting.<\/p>\n\n\n\n

\u201cNovilytic\u2019s technology represents a major disrupter in the pharmaceutical manufacturing industry. It could lead to enhanced FDA compliance in a day and age where transparency and accuracy are paramount,\u201d said Riley Gibb, associate director of Purdue Ventures<\/a>. \u201cWe\u2019re extremely proud to have them in our portfolio of early-stage startups and are looking forward to both the industry reaction to this product as well as Novilytic\u2019s future offerings.\u201d<\/p>\n\n\n

\n
\"\"
The Proteometer-L from Novilytic performs analyses of medicinal antibody batches roughly every 10 minutes. It is designed as a \u2018plug and play\u2019 consumable for more than 250,000 laboratory instruments currently used by the pharmaceutical industry. (Photo provided by Novilytic)<\/figcaption><\/figure>\n<\/div>\n\n\n

In addition to the investment, Purdue Research Foundation worked with Novilytic to create a technology licensing and servicing agreement and provided several industry connections that have resulted in strategic partnerships for the company.<\/p>\n\n\n\n

Novilytic is already planning a large-scale expansion to meet anticipated demand. This includes key hires for product management, operations and the laboratory team. The company is also looking to expand its West Lafayette laboratory and open an Indianapolis-area satellite office. Current job openings include director of analytics, manufacturing engineer and staff analytical scientist. <\/p>\n\n\n\n

The L in the Proteometer-L name stands for Luminon, which is a type of molecular-recognition agent that the company has trademarked. Novilytic plans to release additional Proteometer kits that are assay- and vertical-specific later in 2023. Secondary markets may include, but are not limited to, veterinary health, other antibodies, proteins and the ELISA market. <\/p>\n\n\n\n

About Novilytic LLC<\/h2>\n\n\n\n

Novilytic \u2013 The Canary in the FermentorTM<\/sup> \u2013 is a molecular-recognition company that utilizes nanotechnology to monitor the quality of lifesaving drugs. The company is backed by strong partnerships with large analytical companies, AI leaders and pharmaceutical consortiums. Our potency is extended by the Novilytic team, which includes multiple PhD chemists and engineers who have helped us secure significant patents and other IP. Our business plan will increase those forces to ensure we meet customer, market and regulatory demands. Learn more at Novilytic.com<\/a>.<\/p>\n\n\n\n

About Purdue Research Foundation<\/h2>\n\n\n\n

Purdue Research Foundation is a nonprofit corporation governed by 16 individuals who serve on a board of directors. The PRF Board of Directors meets quarterly to manage the business and affairs of the corporation, to prescribe and enforce policies, and to guide the corporation in achieving its objectives.   <\/p>\n\n\n\n

Purdue Research Foundation supports Purdue University’s land-grant mission by helping the university improve the world through its technologies and graduates. Established in 1930, PRF is a private, nonprofit foundation. The foundation helps patent and commercialize Purdue technologies; builds places to encourage innovation, invention, investment, commercialization and entrepreneurship; and makes equity available to students to finance their Purdue education. For more information on licensing a Purdue innovation, contact the Office of Technology Commercialization at\u00a0otcip@prf.org<\/a>. For more information about involvement and investment opportunities in startups based on a Purdue innovation, contact the Purdue Startup Foundry at\u00a0foundry@prf.org<\/a>.<\/p>\n\n\n

\n
\n
\n

\n Writers\/Media Contacts:<\/strong>\u00a0Ryan Simpson,\u00a0rsimpson@novilytic.com<\/a>
Steve Martin,\u00a0smartin@prf.org<\/a>
Sources:<\/strong>\u00a0Paul Dreier,\u00a0pdreier@novilytic.com<\/a>, 317-752-3116
Riley Gibb\u00a0rtgibb@prf.org<\/a> <\/p>\n <\/div>\n <\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WEST LAFAYETTE, Ind. — Novilytic LLC, a molecular-recognition company that uses nanotechnology to monitor the quality of lifesaving medicines, has released its first product, the Proteometer-L. The company\u2019s goal is that sales from the product will enable rapid hiring for<\/p>\n","protected":false},"author":3,"featured_media":1077,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19,316],"tags":[],"department":[24],"source":[35],"purdue_today_topic":[72],"coauthors":[103],"class_list":["post-1073","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general","category-prf","department-research-foundation","source-purdue-research-foundation","purdue_today_topic-general"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/1073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/comments?post=1073"}],"version-history":[{"count":3,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/1073\/revisions"}],"predecessor-version":[{"id":1082,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/1073\/revisions\/1082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/media\/1077"}],"wp:attachment":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/media?parent=1073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/categories?post=1073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/tags?post=1073"},{"taxonomy":"department","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/department?post=1073"},{"taxonomy":"source","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/source?post=1073"},{"taxonomy":"purdue_today_topic","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/purdue_today_topic?post=1073"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/coauthors?post=1073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}